@Jase99 thank you for your response to my post wherein I expressed some opinions as to Imugene's ongoing downfall in SP value (i.e., as opposed to shareholder value) in recent years.
I note you are correct in assuming Imugene's B cell treatment arm is designed to treat solid tumours as well as some blood cancers. But realistically speaking the development of this platform has been both slow and under funded in contrast to the CF33/Vaxinia, Oncarlytics and Azer Cell platforms, therefore I would view these treatments as being in the minority when assessing Imugene's overall pipeline. Imugene has committed hundreds of millions of dollars in years to come to the development of the allogeneic therapy Azer Cel. To the contrary many of Professor Kaumaya's TIGS, acquired years ago now, have barely even gotten off the ground yet.
I am not confused at all when discussing Imugene's reliance on their CF33/Vaxinia platform. Without the CF33/Vaxinia addition to the Oncarlytics platform Oncarlytics would in my opinion be worth but a fraction of its potential value. Can OnCARlytics treat solid tumours in cancer patients without the addition of CF33/Vaxinia? Pre clinical trials have exhibited significant tumour killing when onCARlytics is combined with CF33, but I am yet to see significant tumour killing from Oncarlytics as a stand alone vessel. Keep in mind OnCARlytics is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver de novo cell surface expression of CD19 antigen (CF33-CD19) promoting CD19-CAR T cell anti-tumor responses against solid tumours.
Azer cel has the potential to obtain strong revenue from blood cancer treatment, particularly in the relapse diffuse B cell lymphoma and leukaemia indications, though as noted in most if not all Imugene announcements and discussions the overriding goal is to combine the allogeneic therapy with both CF33 and Oncarlytics in the fight against much broader solid tumour indications. As noted in Imugene's most recent announcement pertaining to Azer Cel, "Beyond using azer-cel in blood cancers, in the future it will also be combined with Imugene’s own onCARlytics for treatment of patients with solid tumours, opening a potentially large market for azer-cel in the 90% of oncology not beyond blood cancers." Are you assuming this treatment shall be without the addition of CF33/Vaxinia? I think not.
Despite having succeeded in producing comparable results to Roche's breast cancer blockbuster Herceptin, lets be realistic, Her Vaxx is yet to set the world on fire from a commercial perspective. Maybe it was simply a case of Enhertu stealing the B cell vaccines thunder. Likewise PD1 Vaxx, from which I still see strong opportunities in the lung cancer, colorectal and colon cancer indications. But once again as noted in previous posts, this is a rather crowded space, with Jemperli, Keytruda and Opdivo already assuming strong market positions and approval to treat early stage cancer patients.
You are correct in assuming many of Imugene's products are designed to and have the potential to treat solid tumours, but the market clearly has not responded to their initial successes. Hence my piece on the decline in Imugene's share price by over 95% year on year. In my opinion the market is waiting for CF33/Vaxinia to not only succeed in treating solid tumours, but succeed in unleashing the underlying potential of both Oncarlytics and Azer Cel. Therein lies my rational behind the assumption Imugene is heavily reliant on their unique oncolytic viral platform. Either way I guess we shall know in the coming month whether the market placed more weight on CF33/Vaxinia, or on Imugene's other treatment arms, when the forthcoming Vaxinia (MAST) trial results are metered out,.
DYOR Seek investment advice as and when required Opinions only
(20min delay)